Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/58185
Title: Current evidence for diagnosis and management of cardiac vasculitis.
Authors: Khanna S.;Bhat A.;Thomas L.;Arnott C.;Nerlekar N. 
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Khanna, Arnott) Cardiovascular Program, The George Institute for Global Health, Sydney, NSW, Australia
(Khanna, Thomas, Arnott) UNSW, Sydney, NSW, Australia
(Khanna, Nerlekar) Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
(Bhat, Thomas) Department of Cardiology, Westmead Hospital, Westmead, NSW, Australia
(Bhat) Department of Cardiology, Blacktown Hospital, Sydney, NSW, Australia
(Arnott) Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
(Arnott) Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia
(Nerlekar) Victorian Heart Hospital, Monash University, Melbourne, VIC, Australia
(Nerlekar) Monash Heart, Monash Health, Clayton, VIC, Australia
Issue Date: 22-Apr-2026
Copyright year: 2026
Publisher: BMJ Publishing Group
Place of publication: United Kingdom
Publication information: Heart. (no pagination), 2026. Date of Publication: 2026.
Journal: Heart
Abstract: Cardiac vasculitis represents a heterogeneous group of immune-mediated disorders that can involve the coronary vessels, myocardium, valvular apparatus and pericardial tissues. Despite its rarity, cardiac vasculitis may result in significant clinical sequelae such as acute coronary syndrome, heart failure, cardiac arrhythmias and pericarditis. Diagnosis is challenging because symptoms are often non-specific and overlap with other cardiovascular conditions. Early recognition is therefore crucial to prevent delayed treatment and disease progression. Advances in non-invasive multimodality imaging and collaborative cardio-rheumatology care have transformed recognition and management of this disease spectrum. Emerging techniques such as hybrid positron emission tomography-cardiac MRI and quantitative CT imaging permit in-vivo characterisation of inflammation. As per European Alliance of Associations for Rheumatology recommendations, treatment requires early intensive immunosuppression to induce remission, coupled with comprehensive cardiovascular risk management. Additional research is required to validate imaging-guided management algorithms, refine vasculitis-specific cardiovascular risk and define long-term outcomes across disease subtypes.Copyright © Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group.
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1136/heartjnl-2025-327506
PubMed URL: 42009571
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/58185
Type: Article In Press
Subjects: acute coronary syndrome
aortitis
cardiovascular disease
cardiovascular inflammation
cardiovascular magnetic resonance
cardiovascular risk
diagnostic imaging
etiology
heart arrhythmia
heart failure
immune deficiency
immunosuppressive treatment
inflammation
pericarditis
positron emission tomography
remission
therapy
therapy delay
vasculitis
Appears in Collections:Articles

Show full item record

Page view(s)

20
checked on May 23, 2026

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.